Werner Rainer, CEO of XSpline comments on the first patient enrolling in the International Clinical Trial for the company’s Non-Invasive Cardiac Resynchronization Therapy

Werner Rainer, CEO of XSpline comments on the first patient enrolling in the International Clinical Trial for the company's Non-Invasive Cardiac Resynchronization Therapy

Werner Rainer, CEO of XSpline comments on the first patient enrolling in the International Clinical Trial for the company’s Non-Invasive Cardiac Resynchronization Therapy

(IN BRIEF) I am excited to share that XSpline SPA and Ordensklinikum Linz Elisabethinen Hospital have enrolled the first patient in the CRT-DRIVE clinical trial. Our cloud-based XSpline Cloud technology offers non-invasive cardiac panoramic mapping to select individual CRT treatment strategy and predict outcomes. With fast and automatic AI-based segmentation of cardiac structures and identification of the correct target zone for LV lead implantation, we provide a comprehensive tool for successful CRT implantation. The platform is fully operable with existing clinical standards and data formats and provides medical-grade visualization tools for optimal patient care. I am proud of our international team of skilled clinicians, mathematicians, and biomedical engineers, who are dedicated to advancing patient care with innovative technology solutions.

(PRESS RELEASE) BOLZANO / BOZEN, Italy, 21-Mar-2023 — /EuropaWire/ — As CEO of XSpline SPA, I am thrilled to announce that we have enrolled the first patient in the international multicenter clinical study for the Cardiac Resynchronization Therapy DeliveRy guided by non-Invasive electrical and VEnous anatomy assessment (CRT-DRIVE). Our team has developed the XSpline Cloud technology, a cloud-based non-invasive cardiac panoramic mapping technology that can select individual CRT treatment strategy and predict outcomes.

The XSpline Cloud technology includes fast and fully automatic Artificial Intelligence-based epi- and endocardial segmentation of cardiac structures, including coronary sinus veins, providing a clear understanding of the patient’s individual anatomy. With an AI-based identification of the correct target zone for LV lead implantation, XSpline Cloud is the first system in the world to offer this capability.

The cloud-based platform is fully operable with existing clinical standards and data formats and supports a broad range of ECG formats. It also provides embedded medical-grade visualization tools, such as an integrated multimodality DICOM viewer, an ECG viewer with measurement capabilities, a high-performance 3D viewer for segmented cardiac structures and electro-anatomical maps as well as an interactive navigator for LV lead placement.

We believe that the XSpline Cloud software provides a unique approach to selecting an individualized CRT treatment strategy. It is a comprehensive tool for successful CRT implantation that can also predict outcomes, making the implantation procedure faster, easier, and safer for the patient. We are proud to be working with the Ordensklinikum Linz Elisabethinen Hospital in Austria to conduct the CRT-DRIVE clinical trial, which will evaluate the efficacy of XSpline Cloud technology.

While the XSpline Cloud is still an investigational device and not yet approved for commercial use, we are confident that it has the potential to improve patient care and outcomes in the future. At XSpline SPA, our international R&D team of skilled clinicians, mathematicians, and biomedical engineers are dedicated to improving patient care through innovative technology solutions.

Here you can read the original press release announcing the international multicenter clinical study for the Cardiac Resynchronization Therapy DeliveRy.

SOURCE: XSpline SPA, Bolzano/Bozen (Italy)

MORE ON CARDIOLOGY, ETC.:

Follow EuropaWire on Google News
EDITOR'S PICK:

Comments are closed.